Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label retreatment study of venetoclax + obinutuzumab in relapsed chronic lymphocytic leukemia after prior fixed-duration VenG
MOH_2022-06-19_011859Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 cohorts), sponsored by AbbVie Inc. Started Jun 2022; status: recruiting.
02
Drugs
venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2022-06-19_011859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-19_011859.